Skip to main content

Effect of a Ropy Exopolysaccharide-Producing Bifidobacterium animalis subsp. lactis Strain Orally Administered on DSS-Induced Colitis Mice Model

  • 2016-06-09
  • Frontiers in Microbiology 7
    • C. Hidalgo-Cantabrana
    • F. Algieri
    • A. Rodríguez‐Nogales
    • T. Vezza
    • P. Martínez-Camblor
    • A. Margolles
    • P. Ruas-Madiedo
    • J. Gálvez

Abstract

Exopolysaccharide (EPS)-producing bifidobacteria, particularly Bifidobacterium animalis subsp. lactis strains, are used in the functional food industry as promising probiotics with purported beneficial effects. We used three isogenic strains of B. animalis subsp. lactis, with different EPS producing phenotypes (mucoid-ropy and non-ropy), in order to determine their capability to survive the murine gastrointestinal tract transit, as well as to evaluate their role in improving clinical outcomes in a chemically-induced colitis model. The three strains were able to survive in the intestinal tract of C57BL/6J mice during the course of the intervention study. Furthermore, the disease activity index (DAI) of the animal group treated with the ropy strain was significantly lower than of the DAI of the placebo group at the end of the treatment. However, no significant differences were found among the three strains. The analysis of several immune parameters, such as TNFα and IL-10 quantified in blood plasma and lymphocyte populations enumerated in mesenteric nodes, showed some significant variations among the four experimental animal groups. Remarkably, a higher capability of the ropy strain to increase regulatory T-cells in mesenteric lymphoid nodes was demonstrated, suggesting a higher ability of this strain to regulate inflammatory responses at mucosal level. Our data indicate that strains of B. animalis subsp. lactis producing EPS that confer a mucoid-ropy phenotype could represent promising candidates to perform further studies targeting intestinal inflammatory processes.

Keywords: Bifidobacterium; DSS-colitis; exopolysaccharide; immune modulation; mouse model; mucoid; ropy.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium animalisIncreased Regulatory T-Cells in Mesenteric Lymphoid NodesBeneficial
Small
Bifidobacterium animalisReduced Disease Activity Index (DAI) LevelsBeneficial
Moderate
Bifidobacterium animalis subsp. lactisEnhanced Regulatory T-Cells in Mesenteric Lymphoid NodesBeneficial
Moderate
Bifidobacterium animalis subsp. lactisReduced Disease Activity Index in DSS-Induced ColitisBeneficial
Moderate
Bifidobacterium animalis subsp. lactis B420Improved Clinical Outcomes in ColitisBeneficial
Moderate
Bifidobacterium animalis subsp. lactis B420Increased Regulatory T Cell CountBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BLC1Enhanced Regulatory T-Cells in Mesenteric Lymphoid NodesBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BLC1Improved Disease Activity Index for DSS-Induced ColitisBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BS-01Improved Disease Activity Index ScoreBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BS-01Increased Regulatory T Cell CountBeneficial
Moderate
Bifidobacterium animalis subsp. lactis CECT 8145Increased Regulatory T-Cells in Mesenteric Lymphoid NodesBeneficial
Small
Bifidobacterium animalis subsp. lactis CECT 8145Reduced Disease Activity Index in Colitis ModelBeneficial
Moderate
Bifidobacterium animalis subsp. lactis HN019Improved Clinical Outcome in DSS-Induced ColitisBeneficial
Moderate
Bifidobacterium animalis subsp. lactis HN019Increased Regulatory T Cell CountBeneficial
Moderate
Bifidobacterium animalis subsp. lactis LAFTI B94Improved Clinical Outcome in DSS-Induced ColitisBeneficial
Moderate
Bifidobacterium animalis subsp. lactis LAFTI B94Increased Regulatory T-Cells in Mesenteric Lymphoid NodesBeneficial
Small
Bifidobacterium animalis subsp. lactis VK2Increased Regulatory T-Cells in Mesenteric Lymphoid NodesBeneficial
Small
Bifidobacterium animalis subsp. lactis VK2Reduced Disease Activity Index in Colitis ModelBeneficial
Moderate
Bifidobacterium lactisImproved Gastrointestinal SurvivalBeneficial
Moderate
Bifidobacterium lactisIncreased Regulatory T-Cells in Mesenteric Lymphoid NodesBeneficial
Small
Bifidobacterium lactisReduced Colitis Disease ActivityBeneficial
Moderate
Bifidobacterium lactis BI-04Improved Clinical Outcomes in ColitisBeneficial
Moderate
Bifidobacterium lactis BI-04Increased Regulatory T Cell CountBeneficial
Moderate
Bifidobacterium lactis HA-194Increased Regulatory T-Cells in Mesenteric Lymphoid NodesBeneficial
Small
Bifidobacterium lactis HA-194Reduced Disease Activity Index (DAI) LevelsBeneficial
Moderate
Bifidobacterium lactis ISS BifIncreased Regulatory T Cell CountBeneficial
Moderate
Bifidobacterium lactis ISS BifReduced Disease Activity Index (DAI) LevelsBeneficial
Moderate
Bifidobacterium lactis MAK16B42LEnhanced Survival of Bifidobacterium lactis in Gastrointestinal TractBeneficial
Moderate
Bifidobacterium lactis MAK16B42LIncreased Regulatory T-Cells in Mesenteric Lymphoid NodesBeneficial
Small
Bifidobacterium lactis MAK16B42LReduced Disease Activity Index in Colitis ModelBeneficial
Moderate
Bifidobacterium lactis R101-8Improved Clinical Outcome in DSS-Induced ColitisBeneficial
Moderate
Bifidobacterium lactis R101-8Increased Regulatory T-Cells in Mesenteric Lymphoid NodesBeneficial
Small

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.